Functional polymorphisms of interleukin‐18 gene and risk of breast cancer in a Brazilian population

Back, Lia Kubelka de Carlos; Farias, Ticiana Della Justina; Cunha, Patricia; Muniz, Yara Costa Netto; Ribeiro, M. C. M.; Fernandes, Bráulio Leal; Fernandes, Chrystel; Souza, Ilíada Rainha de

doi:10.1111/tan.12367

Cited by 16 publications

(17 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…All association analysis was performed by SNPStats online software in which p < 0.05 is considered statistically significant (Table b and c in Supplementary material). 52 …”

Section: Discussionmentioning

confidence: 99%

Inflammatory breast cancer: High incidence of GCC haplotypes (−1082A/G, −819T/C, and −592A/C) in the interleukin-10 gene promoter correlates with over-expression of interleukin-10 in patients’ carcinoma tissues

et al. 2017

View full text Add to dashboard Cite

Interleukin-10 is involved in carcinogenesis by supporting tumor escape from the immune response. The aim of this study was to assess the single nucleotide polymorphisms, −1082A/G, −819T/C and −592A/C, in interleukin-10 gene promoter in inflammatory breast cancer compared to non-inflammatory breast cancer and association of these polymorphisms with interleukin-10 gene expression. We enrolled 105 breast cancer tissue (72 non-inflammatory breast cancer and 33 inflammatory breast cancer) patients and we determined the three studied single nucleotide polymorphisms in all samples by polymerase chain reaction restriction fragment length polymorphism and investigated their association with the disease and with various prognostic factors. In addition, we assessed the expression of interleukin-10 gene by realtime quantitative reverse transcription polymerase chain reaction and the correlation between studied single nucleotide polymorphisms and interleukin-10 messenger RNA expression. We found co-dominant effect as the best inheritance model (in the three studied single nucleotide polymorphisms in non-inflammatory breast cancer and inflammatory breast cancer samples), and we didn't identify any association between single nucleotide polymorphisms genotypes and breast cancer prognostic factors. However, GCC haplotype was found highly associated with inflammatory breast cancer risk (p < 0.001, odds ratio = 43.05). Moreover, the expression of interleukin-10 messenger RNA was significantly higher (p < 0.001) by 5.28-fold and 8.95-fold than non-inflammatory breast cancer and healthy control, respectively, where GCC haplotype significantly increased interleukin-10 gene expression (r = 0.9, p < 0.001).

show abstract

“…All association analysis was performed by SNPStats online software in which p < 0.05 is considered statistically significant (Table b and c in Supplementary material). 52 …”

Section: Discussionmentioning

confidence: 99%

Inflammatory breast cancer: High incidence of GCC haplotypes (−1082A/G, −819T/C, and −592A/C) in the interleukin-10 gene promoter correlates with over-expression of interleukin-10 in patients’ carcinoma tissues

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Indeed, the association of the several inflammatory or immune response-related gene polymorphisms such as CXCL12, IL-18, IL-21, IFN-γ, and TNF-α with breast cancer have been reported in different populations [24][25][26][27]. It has been reported that chemokines genetic variations may influence the susceptibility to some infectious diseases and also to a variety of noninfectious diseases such as cancer, autoimmune, and cardiovascular diseases [28].…”

Section: Introductionmentioning

confidence: 99%

Higher circulating levels of chemokine CCL22 in patients with breast cancer: evaluation of the influences of tumor stage and chemokine gene polymorphism

et al. 2014

View full text Add to dashboard Cite

The receptor for CCL22 is named CCR4 that preferentially is expressed on the regulatory T cells (Treg), and accordingly, CCL22 acts as a chemoattractant for the intratumoral Treg migration. The aim of this study was to evaluate the serum CCL22 levels and a single nucleotide polymorphism (SNP) in chemokine gene, [2030 G/C (rs223818)], in patients with breast cancer. Blood samples were collected from 100 women with breast cancer before receiving chemotherapy, radiotherapy, or immunotherapy and 100 age-matched healthy women as a control group. The serum CCL22 levels were measured by ELISA. The DNA extracted and the SNP rs223818 determined by amplification refractory mutation system-polymerase chain reaction (ARMS-PCR) technique. The mean serum CCL22 levels in patients with breast cancer (2398.5 ± 123 Pg/mL) was significantly higher in comparison to healthy control group (974.2 ± 39.9 Pg/mL; P < 0.001). According to the tumor stages, the mean serum levels of CCL22 were 999.8 ± 85.0 Pg/mL in stage I, 1718.8 ± 82.3 Pg/mL in stage II, 2846.8 ± 118.0 Pg/mL in stage III, and 3954.5 ± 245.2 Pg/mL in stage IV. There was significant difference between tumor stages regarding the serum CCL22 levels (P < 0.001). In patients with breast cancer, the frequencies of CC genotype (63%) and C allele (79%) at rs223818 were significantly higher as compared to healthy controls (31 and 52%, respectively; P < 0.001). In both patients and control groups, the mean serum levels of CCL22 in subjects with CC genotype or C allele at rs223818 were also significantly higher as compared to subjects with GG genotype or G allele (P < 0.001). Higher serum CCL22 levels were observed in patients with breast cancer that is increased with advanced stages. These findings represent that the CCL22 may contribute in tumor development. The CC genotype and C allele at rs223818 were more frequent in breast cancer patients. The serum CCL22 levels were affected by genetic variations at SNP rs223818. Accordingly, SNP rs223818 may play a role in the susceptibility to breast cancer.

show abstract

“…Furthermore, the association was verified between the 2 SNPs and the susceptibility to many cancers, including hepatocellular carcinoma, non‐small‐cell lung cancer, papillary thyroid carcinoma, chronic leukemia, oral squamous cell carcinoma . Although there have been reports on the association analysis of the IL‐18 ‐137, and ‐607 sites with susceptibility to breast cancer, but the conclusions are not consistent …”

Section: Discussionmentioning

confidence: 93%

“…However, studies focus on the role of IL‐18 polymorphisms on the risk of breast cancer remain controversial. To the best of our knowledge, only 3 studies have estimated the impact of IL‐18 polymorphisms ‐137G/C and/or ‐607A/C on breast cancer susceptibility . Khalili et al recruited 200 breast cancer patients and 206 healthy controls to examine the effect of ‐607A/C and ‐137G/C gene polymorphism of IL‐18 on breast cancer risk.…”

Section: Introductionmentioning

confidence: 99%

“…Back et al recruited 154 breast cancer patients and 118 healthy controls to evaluated the association of ‐607A/C and ‐137G/C gene polymorphism with breast cancer risk. Their result suggested that IL‐18‐607A/C and ‐137G/C polymorphism contribute to increase the breast cancer risk . No study has taken the interaction between the 2 SNPs and body mass index (BMI), menopause in the course of the development of breast cancer into consideration.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Association analysis of interleukin‐18 gene promoter region polymorphisms and susceptibility to sporadic breast cancer in Chinese Han women

Qiao

Xu²,

Sun

et al. 2018

Clinical Laboratory Analysis

View full text Add to dashboard Cite

show abstract

Functional polymorphisms of interleukin‐18 gene and risk of breast cancer in a Brazilian population

Cited by 16 publications

References 38 publications

Inflammatory breast cancer: High incidence of GCC haplotypes (−1082A/G, −819T/C, and −592A/C) in the interleukin-10 gene promoter correlates with over-expression of interleukin-10 in patients’ carcinoma tissues

Inflammatory breast cancer: High incidence of GCC haplotypes (−1082A/G, −819T/C, and −592A/C) in the interleukin-10 gene promoter correlates with over-expression of interleukin-10 in patients’ carcinoma tissues

Higher circulating levels of chemokine CCL22 in patients with breast cancer: evaluation of the influences of tumor stage and chemokine gene polymorphism

Association analysis of interleukin‐18 gene promoter region polymorphisms and susceptibility to sporadic breast cancer in Chinese Han women

Contact Info

Product

Resources

About